{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:19:28Z","timestamp":1791505168549,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) is impaired in up to 50% of patients due to chemoresistance, with no predictive biomarkers in clinical use. The proto-oncogene RNA-binding motif protein 3 (RBM3) has emerged as a putative modulator of chemotherapy response in several solid tumours but has a hitherto unrecognized role in MIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RBM3 protein expression level in tumour cells was assessed via immunohistochemistry in paired transurethral resection of the bladder (TURB) specimens, cystectomy specimens and lymph node metastases from a consecutive cohort of 145 patients, 65 of whom were treated with NAC. Kaplan-Meier and Cox regression analyses were applied to estimate the impact of RBM3 expression on time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) in strata according to NAC treatment. The effect of siRNA-mediated silencing of RBM3 on chemosensitivity was examined in RT4 and T24 human bladder carcinoma cells in vitro. Cellular functions of RBM3 were assessed using RNA-sequencing and gene ontology analysis, followed by investigation of cell cycle distribution using flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RBM3 protein expression was significantly higher in TURB compared to cystectomy specimens but showed consistency between primary tumours and lymph node metastases. Patients with high-tumour specific RBM3 expression treated with NAC had a significantly reduced risk of recurrence and a prolonged CSS and OS compared to NAC-untreated patients. In high-grade T24 carcinoma cells, which expressed higher\n                      <jats:italic>RBM3<\/jats:italic>\n                      mRNA levels compared to RT4 cells, RBM3 silencing conferred a decreased sensitivity to cisplatin and gemcitabine. Transcriptomic analysis revealed potential involvement of RBM3 in facilitating cell cycle progression, in particular G\n                      <jats:sub>1<\/jats:sub>\n                      \/S-phase transition, and initiation of DNA replication. Furthermore, siRBM3-transfected T24 cells displayed an accumulation of cells residing in the G\n                      <jats:sub>1<\/jats:sub>\n                      -phase as well as altered levels of recognised regulators of G\n                      <jats:sub>1<\/jats:sub>\n                      -phase progression, including Cyclin D1\/CDK4 and CDK2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The presented data highlight the potential value of RBM3 as a predictive biomarker of chemotherapy response in MIBC, which could, if prospectively validated, improve treatment stratification of patients with this aggressive disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-09168-7","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T11:06:34Z","timestamp":1643799994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity"],"prefix":"10.1186","volume":"22","author":[{"given":"Sara","family":"Wahlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Boman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Nodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Karnevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"issue":"3","key":"9168_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1006\/bbrc.1997.7059","volume":"236","author":"S Danno","year":"1997","unstructured":"Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, et al. Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun. 1997;236(3):804\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"44","key":"9168_CR2","doi-asserted-by":"publisher","first-page":"40680","DOI":"10.1074\/jbc.M102399200","volume":"276","author":"CF Wright","year":"2001","unstructured":"Wright CF, Oswald BW, Dellis S. Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J Biol Chem. 2001;276(44):40680\u20136.","journal-title":"J Biol Chem"},{"issue":"5","key":"9168_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/j.1471-4159.2007.04521.x","volume":"101","author":"F Smart","year":"2007","unstructured":"Smart F, Aschrafi A, Atkins A, Owens GC, Pilotte J, Cunningham BA, et al. Two isoforms of the cold-inducible mRNA-binding protein RBM3 localize to dendrites and promote translation. J Neurochem. 2007;101(5):1367\u201379.","journal-title":"J Neurochem"},{"issue":"33","key":"9168_CR4","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1038\/onc.2008.97","volume":"27","author":"SM Sureban","year":"2008","unstructured":"Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene. 2008;27(33):4544\u201356.","journal-title":"Oncogene."},{"issue":"12","key":"9168_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028446","volume":"6","author":"J Pilotte","year":"2011","unstructured":"Pilotte J, Dupont-Versteegden EE, Vanderklish PW. Widespread regulation of miRNA biogenesis at the dicer step by the cold-inducible RNA-binding protein, RBM3. PLoS One. 2011;6(12):e28446.","journal-title":"PLoS One"},{"issue":"1","key":"9168_CR6","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1038\/s41598-018-25668-2","volume":"8","author":"J Pilotte","year":"2018","unstructured":"Pilotte J, Kiosses W, Chan SW, Makarenkova HP, Dupont-Versteegden E, Vanderklish PW. Morphoregulatory functions of the RNA-binding motif protein 3 in cell spreading, polarity and migration. Sci Rep. 2018;8(1):7367.","journal-title":"Sci Rep"},{"issue":"Pt 9","key":"9168_CR7","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1242\/jcs.01026","volume":"117","author":"S Wellmann","year":"2004","unstructured":"Wellmann S, B\u00fchrer C, Moderegger E, Zelmer A, Kirschner R, Koehne P, et al. Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci. 2004;117(Pt 9):1785\u201394.","journal-title":"J Cell Sci"},{"issue":"2","key":"9168_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1096\/fj.15-274639","volume":"30","author":"X Zhu","year":"2016","unstructured":"Zhu X, Zelmer A, Kapfhammer JP, Wellmann S. Cold-inducible RBM3 inhibits PERK phosphorylation through cooperation with NF90 to protect cells from endoplasmic reticulum stress. FASEB J. 2016;30(2):624\u201334.","journal-title":"FASEB J"},{"issue":"1","key":"9168_CR9","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1038\/s41467-019-11870-x","volume":"10","author":"X Zhu","year":"2019","unstructured":"Zhu X, Yan J, Bregere C, Zelmer A, Goerne T, Kapfhammer JP, et al. RBM3 promotes neurogenesis in a niche-dependent manner via IMP2-IGF2 signaling pathway after hypoxic-ischemic brain injury. Nat Commun. 2019;10(1):3983.","journal-title":"Nat Commun"},{"key":"9168_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1479-5876-9-114","volume":"9","author":"L Jonsson","year":"2011","unstructured":"Jonsson L, Bergman J, Nodin B, Manjer J, Pont\u00e9n F, Uhl\u00e9n M, et al. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malm\u00f6 diet and cancer study. J Transl Med. 2011;9:114.","journal-title":"J Transl Med"},{"issue":"8","key":"9168_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182512","volume":"12","author":"C Siesing","year":"2017","unstructured":"Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pont\u00e9n F, et al. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS One. 2017;12(8):e0182512.","journal-title":"PLoS One"},{"issue":"11\u201312","key":"9168_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/prca.201100020","volume":"5","author":"B Hjelm","year":"2011","unstructured":"Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, et al. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. 2011;5(11\u201312):624\u201335.","journal-title":"Proteomics Clin Appl"},{"key":"9168_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-017-0090-y","volume":"5","author":"K Boman","year":"2017","unstructured":"Boman K, Andersson G, Wennersten C, Nodin B, Ahlgren G, Jirstr\u00f6m K. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study. Biomark Res. 2017;5:10.","journal-title":"Biomark Res"},{"key":"9168_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2490-13-17","volume":"13","author":"K Boman","year":"2013","unstructured":"Boman K, Segersten U, Ahlgren G, Eberhard J, Uhl\u00e9n M, Jirstr\u00f6m K, et al. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol. 2013;13:17.","journal-title":"BMC Urol"},{"issue":"12","key":"9168_CR15","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/modpathol.2009.124","volume":"22","author":"A J\u00f6gi","year":"2009","unstructured":"J\u00f6gi A, Brennan DJ, Ryd\u00e9n L, Magnusson K, Fern\u00f6 M, St\u00e5l O, et al. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol. 2009;22(12):1564\u201374.","journal-title":"Mod Pathol"},{"key":"9168_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1479-5876-8-78","volume":"8","author":"A Ehl\u00e9n","year":"2010","unstructured":"Ehl\u00e9n A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 2010;8:78.","journal-title":"J Transl Med"},{"issue":"13","key":"9168_CR17","doi-asserted-by":"publisher","first-page":"22235","DOI":"10.18632\/oncotarget.14755","volume":"8","author":"RB Zhou","year":"2017","unstructured":"Zhou RB, Lu XL, Zhang CY, Yin DC. RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection. Oncotarget. 2017;8(13):22235\u201350.","journal-title":"Oncotarget."},{"issue":"5","key":"9168_CR18","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.18632\/oncotarget.23486","volume":"9","author":"E Karnevi","year":"2018","unstructured":"Karnevi E, Dror LB, Mardinoglu A, Elebro J, Heby M, Olofsson SE, et al. Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Oncotarget. 2018;9(5):6188\u2013200.","journal-title":"Oncotarget."},{"key":"9168_CR19","volume":"2013","author":"FC Lee","year":"2013","unstructured":"Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, et al. Pathologic response rates of gemcitabine\/cisplatin versus methotrexate\/vinblastine\/adriamycin\/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv Urol. 2013;2013:317190.","journal-title":"Adv Urol"},{"issue":"6","key":"9168_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ull\u00e9n A, Nilsson S, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229\u201338.","journal-title":"Eur Urol"},{"issue":"6","key":"9168_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes Predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68(6):959\u201367.","journal-title":"Eur Urol"},{"issue":"3","key":"9168_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","volume":"69","author":"FH Groenendijk","year":"2016","unstructured":"Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69(3):384\u20138.","journal-title":"Eur Urol"},{"issue":"3","key":"9168_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A, et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res. 2019;25(3):977\u201388.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9168_CR24","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4(10):1140\u201353.","journal-title":"Cancer Discov"},{"issue":"1","key":"9168_CR25","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020;11(1):4858.","journal-title":"Nat Commun"},{"issue":"4","key":"9168_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"},{"issue":"4","key":"9168_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544\u201354.","journal-title":"Eur Urol"},{"issue":"7","key":"9168_CR28","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-04-1988","volume":"11","author":"R Takata","year":"2005","unstructured":"Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11(7):2625\u201336.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9168_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1644108","volume":"8","author":"S Wahlin","year":"2019","unstructured":"Wahlin S, Nodin B, Leandersson K, Boman K, Jirstr\u00f6m K. Clinical impact of T cells, B cells and the PD-1\/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. Oncoimmunology. 2019;8(11):e1644108.","journal-title":"Oncoimmunology."},{"issue":"1","key":"9168_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics."},{"issue":"7","key":"9168_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics."},{"issue":"12","key":"9168_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"key":"9168_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2105-10-48","volume":"10","author":"E Eden","year":"2009","unstructured":"Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009;10:48.","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"9168_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.acuro.2013.01.005","volume":"37","author":"J Huguet","year":"2013","unstructured":"Huguet J. Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp. 2013;37(6):376\u201382.","journal-title":"Actas Urol Esp"},{"issue":"3","key":"9168_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ijc.2910110327","volume":"11","author":"J Buben\u00edk","year":"1973","unstructured":"Buben\u00edk J, Baresov\u00e1 M, Viklick\u00fd V, Jakoubkov\u00e1 J, Sainerov\u00e1 H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. 1973;11(3):765\u201373.","journal-title":"Int J Cancer"},{"issue":"1","key":"9168_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.cr.7290031","volume":"10","author":"D Donjerkovic","year":"2000","unstructured":"Donjerkovic D, Scott DW. Regulation of the G1 phase of the mammalian cell cycle. Cell Res. 2000;10(1):1\u201316.","journal-title":"Cell Res"},{"issue":"1","key":"9168_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1203\/PDR.0b013e3181c13326","volume":"67","author":"S Wellmann","year":"2010","unstructured":"Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, et al. The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res. 2010;67(1):35\u201341.","journal-title":"Pediatr Res"},{"key":"9168_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ebiom.2019.06.030","volume":"45","author":"W Dong","year":"2019","unstructured":"Dong W, Dai ZH, Liu FC, Guo XG, Ge CM, Ding J, et al. The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production. EBioMedicine. 2019;45:155\u201367.","journal-title":"EBioMedicine."},{"issue":"3","key":"9168_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121300","volume":"10","author":"SE Olofsson","year":"2015","unstructured":"Olofsson SE, Nodin B, Gaber A, Eberhard J, Uhl\u00e9n M, Jirstr\u00f6m K, et al. Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer. PLoS One. 2015;10(3):e0121300.","journal-title":"PLoS One"},{"issue":"3","key":"9168_CR40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/carcin\/bgi266","volume":"27","author":"RA Crallan","year":"2006","unstructured":"Crallan RA, Georgopoulos NT, Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis. 2006;27(3):374\u201381.","journal-title":"Carcinogenesis."},{"key":"9168_CR41","doi-asserted-by":"publisher","first-page":"38531","DOI":"10.1038\/srep38531","volume":"6","author":"JI Warrick","year":"2016","unstructured":"Warrick JI, Walter V, Yamashita H, Chung E, Shuman L, Amponsa VO, et al. FOXA1, GATA3 and PPAR\u0263 cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines. Sci Rep. 2016;6:38531.","journal-title":"Sci Rep"},{"issue":"2","key":"9168_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/BLC-180167","volume":"4","author":"TCM Zuiverloon","year":"2018","unstructured":"Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D. Systematic review: characteristics and preclinical uses of bladder cancer cell lines. Bladder Cancer. 2018;4(2):169\u201383.","journal-title":"Bladder Cancer"},{"issue":"7","key":"9168_CR43","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1258\/ebm.2010.009322","volume":"235","author":"GN da Silva","year":"2010","unstructured":"da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos J\u00fanior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood). 2010;235(7):814\u201324.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"47","key":"9168_CR44","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265\u201379.","journal-title":"Oncogene."},{"issue":"4","key":"9168_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1593\/tlo.11106","volume":"4","author":"\u00c5 Ehl\u00e9n","year":"2011","unstructured":"Ehl\u00e9n \u00c5, Nodin B, Rexhepaj E, Br\u00e4ndstedt J, Uhl\u00e9n M, Alvarado-Kristensson M, et al. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol. 2011;4(4):212\u201321.","journal-title":"Transl Oncol"},{"key":"9168_CR46","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fcell.2019.00288","volume":"7","author":"J Yan","year":"2019","unstructured":"Yan J, Goerne T, Zelmer A, Guzman R, Kapfhammer JP, Wellmann S, et al. The RNA-binding protein RBM3 promotes neural stem cell (NSC) proliferation under hypoxia. Front Cell Dev Biol. 2019;7:288.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"9168_CR47","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1128\/MMBR.00019-09","volume":"73","author":"ML Bochman","year":"2009","unstructured":"Bochman ML, Schwacha A. The mcm complex: unwinding the mechanism of a replicative helicase. Microbiol Mol Biol Rev. 2009;73(4):652\u201383.","journal-title":"Microbiol Mol Biol Rev"},{"key":"9168_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12957-015-0730-3","volume":"13","author":"L Florianova","year":"2015","unstructured":"Florianova L, Xu B, Traboulsi S, Elmansi H, Tanguay S, Aprikian A, et al. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study. World J Surg Oncol. 2015;13:317.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"9168_CR49","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comp\u00e9rat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462\u201375.","journal-title":"Eur Urol"},{"issue":"9","key":"9168_CR50","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09168-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09168-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09168-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:11:04Z","timestamp":1650276664000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09168-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9168"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09168-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"16 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics committee at Lund University (reference number 445-2007). In accordance with national legislation and institutional requirements, the committee waived the need for informed consent other than the option to opt out. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"W.M. Gallagher is a co-founder, shareholder and Chief Scientific Officer in OncoMark Limited, and reports receiving commercial research grants from and is an unpaid Scientific Advisory Board member with Carrick Therapeutics. The other authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}